[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. [2] McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability[J].Clin Liver Dis, 2015, 19(2):223-238. [3] Xu W, Zhang X, Wu JL, et al.O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress[J].J Hepatol, 2017, 67(2):310-320. [4] Zhu Q, Zhou L, Yang Z, et al.O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation[J]. Med Oncol, 2012, 29(2): 985-993. [5] Ma Z, Vosseller K.Cancer metabolism and elevated O-GlcNAc in oncogenic signaling[J]. J Biol Chem, 2014, 289(50):34457-34465. [6] 张肖冰, 师以康. 蛋白质O-GlcNAc糖基化与肿瘤[J]. 肿瘤, 2013, 33(11):1027-1032. [7] Bupathi M, Kaseb A, Janku F.Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives[J]. Onco Targets Ther, 2014, 7:1927-1932. [8] Fodor D, Jung I, Turdean S, et al.Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study[J]. World J Hepatol, 2019, 11(3):294-304. [9] Yoshiji H, Kuriyama S, Noguchi R, et al.Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice[J].Gut, 2005, 54(12):1768-1775. [10] Scholz A, Rehm VA, Rieke S,et al.Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma[J]. Am J Gastroenterol, 2007, 102(11): 2471-2481. [11] Mitsuhashi N, Shimizu H, Ohtsuka M, et al.Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma[J].Hepatology, 2003, 37(5): 1105-1113. [12] 张舒曼, 王源, 李淑莲. 间断低剂量二乙基亚硝胺诱导 C57BL /6J 小鼠肝癌模型[J]. 河南大学学报: 医学版, 2019, 38(2):110-112. [13] Chaparro M, Sanz-Cameno P, Trapero-Marugan M, et al.Mechanisms of angiogenesis in chronic inflammatory liver disease[J].Ann Hepatol, 2007, 6(4):208-213. [14] Verna L, Whysner J, Williams GM.N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation[J].Pharmacol Ther, 1996, 71(1-2):57-81. [15] 李果, 朱柱, 戴小明, 等. 肝癌动物模型建立的研究进展[J]. 医学综述, 2018, 24(2):285-289. [16] 赛文莉, 姚登福, 邰伯军. 血管生成素2对肝癌的发生和发展及治疗的研究进展[J]. 中华临床医师杂志: 电子版, 2010, 4(4):471-473. [17] Wada H, Nagano H, Yamamoto H, et al.Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins[J]. Oncol Rep, 2007, 18(4):801-809. |